Capricor Therapeutics (NASDAQ:CAPR) Given New $12.00 Price Target at Roth Capital

Capricor Therapeutics (NASDAQ:CAPR) had its price objective decreased by investment analysts at Roth Capital from $31.00 to $12.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective suggests a potential upside of 62.69% from the company’s current price.

A number of other brokerages also recently commented on CAPR. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Alliance Global Partners assumed coverage on shares of Capricor Therapeutics in a research note on Monday, June 30th. They set a “buy” rating and a $20.00 price target for the company. B. Riley started coverage on shares of Capricor Therapeutics in a research note on Thursday, June 26th. They issued a “buy” rating and a $21.00 target price for the company. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Oppenheimer dropped their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating for the company in a research note on Monday, June 23rd. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.56.

Capricor Therapeutics Stock Performance

Shares of CAPR traded down $0.26 during midday trading on Monday, hitting $7.38. 2,177,820 shares of the stock were exchanged, compared to its average volume of 2,075,618. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The stock has a fifty day simple moving average of $10.33 and a 200 day simple moving average of $12.09. The firm has a market cap of $336.94 million, a P/E ratio of -5.21 and a beta of 0.82.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the company earned ($0.31) earnings per share. As a group, equities research analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in Capricor Therapeutics by 32.6% in the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock worth $1,160,000 after purchasing an additional 20,638 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Capricor Therapeutics by 51.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 37,868 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $78,000. Swiss National Bank bought a new stake in Capricor Therapeutics in the 4th quarter valued at $930,000. Finally, Intech Investment Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at $228,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.